Role of autologous and allogeneic stem cell transplantation in myeloma

Leukemia

Volumn 23, Issue 3, 2009, Pages 442-448

  Bensinger, W I ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; BORTEZOMIB; BUSULFAN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; DOXORUBICIN; FLUDARABINE; IMMUNOMODULATING AGENT; LENALIDOMIDE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PROTEASOME INHIBITOR; STEROID; THALIDOMIDE; THYMOCYTE ANTIBODY; VINCRISTINE;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL TRIAL; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; FOLLOW UP; HUMAN; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NONHUMAN; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; WHOLE BODY RADIATION;

EID: 62649122863     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2008.396     Document Type: Review

References (66)

1. Dispenzieri A, Zhang L, Fonesca R, Vesole DH, Greipp PR. Single agent bortezomib is associated with a high response rate in patients with high risk multiple myeloma. A phase II study from the Eastern Cooperative Oncology Group (E2A02). Blood 2006; 108 (Part 1): 1006a, no. 3527 (abstract).
2. Anderson KC. The role of immunomodulatory drugs in multiple myeloma (review). Semin Hematol 2003; 40: 23-32.
3. Lacy M, Gertz M, Dispenzieri A, Hayman S, Geyer S, Zeldenrust S et al Lenalidomide plus dexamethasone (Rev/Dex) in newly diagnosed myeloma: Response to therapy, time to progression, and survival. Blood 2006; 108 (Part 1): 239a, no. 798 (abstract).
4. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487-2498.
5. Buckner CD, Fefer A, Bensinger WI, Storb R, Durie BG, Appelbaum FR et al. Marrow transplantation for malignant plasma cell disorders: summary of the Seattle Experience. Eur J Haematol 1989; 43: 186-190.
6. Gahrton G, Svensson H, Björkstrand B, Apperley J, Carlson K, Cavo M et al. Syngeneic transplantation in multiple myeloma - a case-matched comparison with autologous and allogeneic transplantation. Bone Marrow Transplant 1999; 24: 741-745.
7. Bensinger WI, Demirer T, Buckner CD, Appelbaum FR, Storb R, Lilleby K et al. Syngeneic marrow transplantation in patients with multiple myeloma. Bone Marrow Transplant 1996; 18: 527-531.
8. McElwain TJ, Powles RL. High-dose intravenous melphalan for plasma cell leukaemia and myeloma. Lancet 1983; 1: 822-824.
9. Attal M, Harousseau J-L, Stoppa A-M, Sotto J-J, Fuzibet J-G, Rossi J-F et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. N Engl J Med 1996; 335: 91-97.
10. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
11. Fermand J-P, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: Up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998; 92: 3131-3136.
12. Blade J, Rosinol L, Sureda A, Ribera JM, Diaz-Mediavilla J, Garcia-Larana J et al. High-dose therapy intensification compared with continued standard chemotherapy in multiple myeloma patients responding to the initial chemotherapy: Long-term results from a prospective randomized trial from the Spanish cooperative group PETHEMA. Blood 2005; 106: 3755-3759.
13. Barlogie B, Kyle RA, Anderson KC, Greipp PR, Lazarus HM, Hurd DD et al. Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: Final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006; 24: 929-936.
14. Attal M, Harousseau JL, Stoppa AM, Sotto JJ, Fuzibet G, Rossi JF et al. High dose therapy in multiple myeloma: An updated analysis of the IFM 90 protocol. Blood 1998; 92 (Suppl 1): 418a, no.1858 (abstract).
15. Fermand J-P, Ravaud P, Katsahian S, Divine M, Leblond V, Belanger C et al. High dose therapy (HDT) and autologous blood stem cell (ABSC) transplantation versus conventional treatment in multiple myeloma (MM): results of a randomized trial in 190 patients 55-65 years of age. Blood 1999; 94 (Suppl. 1): 396a, no. 1754 (abstract).
16. Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus F, Macro M et al. High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55-65 years: Long-term results of a randomized control trial from the Group Myelome-Autogreffe. J Clin Oncol 2005; 23: 9227-9233.
17. Stewart AK, Vescio R, Schiller G, Ballester O, Noga S, Rugo H et al Purging of autologous peripheral-blood stem cells using CD34 selection does not improve overall or progression-free survival after high-dose chemotherapy for multiple myeloma: Results of a multicenter randomized controlled trial. J Clin Oncol 2001; 19: 3771-3779.
18. Barbui AM, Galli M, Dotti G, Belli N, Borleri G, Gritti G et al. Negative selection of peripheral blood stem cells to support a tandem autologous transplantation programme in multiple myeloma. Br J Haematol 2002; 116: 202-210.
19. Bashey A, Perez WS, Zhang MJ, Anderson KC, Ballen K, Berenson JR et al. Comparison of twin and autologous transplants for multiple myeloma. Biol Blood Marrow Transplant 2008; 14: 1118-1124.
20. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, Fuzibet JG et al Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 2003; 349: 2495-2502.
21. Cavo M, Tosi P, Zamagni E, Cellini C, Tacchetti P, Patriarca F et al Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007; 25: 2434-2441.
22. Morris C, Iacobelli S, Brand R, Bjorkstrand B, Drake M, Niederwieser D et al. Benefit and timing of second transplantations in multiple myeloma: Clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study. J Clin Oncol 2004; 22: 1674-1681.
23. Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Litzow MR, Henderson KJ et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005; 106: 2837-2840.
24. Facon T, Avet-Loiseau H, Guillerm G, Moreau P, Genevieve F, Zandecki M et al. Chromosome 13 abnormalities identified by FISH analysis and serum beta2-microglobulin produce a powerful myeloma staging system for patients receiving high-dose therapy. Blood 2001; 97: 1566-1571.
25. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C et al. Genetic abnormalities and survival in multiple myeloma: The experience of the Intergroupe Francophone du Myelome. Blood 2007; 109: 3489-3495.
26. Attal M, Harousseau JL, Leyvraz S, Doyen C, Hulin C, Benboubker L et al. Maintenance therapy with thalidomide improves survival in patients with multiple myeloma. Blood 2006; 108: 3289-3294.
27. Abdelkefi A, Ladeb S, Torjman L, Othman TB, Lakhal A, Romdhane NB et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: Results of a multicenter randomized clinical trial. Blood 2008; 111: 1805-1810.
28. Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354: 1021-1030.
29. Zangari M, van Rhee F, Anaissie E, Pineda-Roman M, Haessler J, Crowley J et al. Eight-year median survival in multiple myeloma after total therapy 2: Roles of thalidomide and consolidation chemotherapy in the context of total therapy 1. Br J Haematol 2008; 141: 433-444.
30. Harousseau JL, Mathiot C, Attal M, Marit G, Caillot D, Hullin T et al Bortezomib/dexamethasone versus VAD as induction prior to autologous stem cell transplantation (ASCT) in previously untreated multiple myeloma (MM): Updated data from IFM 2005/01 trial. J Clin Oncol 2008; 26 (Part 1): 455S, no. 8505 (abstract).
31. Cavo M, Patriarca F, Tacchetti P, Galli MA, Perrone G, Petrucci MT et al. Bortezomib (Velcade®)-thalidomide-dexamethasone (VTD) vs thalidomide-dexamethasone (VD) in preparation for autologous stem-cell (SC) transplantation (ASCT) in newly diagnosed multiple myeloma (MM). Blood 2007; 110 (Part 1): 30A, no. 73 (abstract).
32. Rajkumar SV, Jacobus S, Callander N, Fonseca R, Vesole D, Williams MV et al. Randomized trial of lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone in newly diagnosed myeloma (E4A03), a trial coordinated by the Eastern Cooperative Oncology Group: Analysis of response, survival, and outcome wi. J Clin Oncol 2008; 26 (Part 1): 455S, no. 8504 (abstract).
33. Macro M, Divine M, Uzunhan Y, Jaccard A, Bouscary D, Leblond V et al Dexamethasone+thalidomide (Dex/Thal) compared to VAD as a pre-transplant treatment in newly diagnosed multiple myeloma (MM): A randomized trial. Blood 2008; 108 (Part 1): 22a, no. 57 (abstract).
34. Dingli D, Pacheco JM, Nowakowski GS, Kumar SK, Dispenzieri A, Hayman SR et al. Relationship between depth of response and outcome in multiple myeloma. J Clin Oncol 2007; 25: 4933-4937.
35. Lahuerta JJ, Mateos MV, Martínez-López J, Rosinõll L, Sureda A, de la Rubia J et al. Influence of pre-and post-transplantation responses on outcome of patients with multiple myeloma: Sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 2008; 26: 5775-5782.
36. Chiriva-Internati M, Wang Z, Salati E, Bumm K, Barlogie B, Lim SH. Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma. Blood 2002; 100: 961-965.
37. Schuetze SM, Smith BE, Kelly D, Maloney DG. Posttransplant immunotherapy for multiple myeloma using idiotype vaccines. In: Dicke KA, Keating A (eds). Autologous Blood and Marrow Transplantation: Proceedings of the Tenth International Symposium, Dallas Texas. Carden Jennings Publishing: Charlottesville, VA, 2001, pp 267-281.
38. Szmania S, Gnjatic S, Tricot G, Stone K, Zhan F, Moreno A et al. Immunization with a recombinant MAGE-A3 protein after high-dose therapy for myeloma. J Immunother 2007; 30: 847-854.
39. Curti A, Tosi P, Comoli P, Terragna C, Ferri E, Cellini C et al. Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient-specific tumour idiotype protein or idiotype (VDJ)-derived class I-restricted peptides. Br J Haematol 2007; 139: 415-424.
40. Harrison SJ, Cook G, Nibbs RJ, Prince HM. Immunotherapy of multiple myeloma: The start of a long and tortuous journey (review). Expert Rev Anticancer Ther 2006; 6: 1769-1785.
41. Tricot G, Vesole DH, Jagannath S, Hilton J, Munshi N, Barlogie B. Graft-versus-myeloma effect: Proof of principle. Blood 1996; 87 1196-1198.
42. Verdonck LF, Lokhorst HM, Dekker AW, Nieuwenhuis HK, Petersen EJ. Graft-versus-myeloma effect in two cases. Lancet 1996; 347: 800-801.
43. Aschan J, Lonnqvist B, Ringden O, Kumlien G, Gahrton G. Graft-versus-myeloma effect (Letter). Lancet 1996; 348: 346.
44. Björkstrand B, Ljungman P, Svensson H, Hermans J, Alegre A, Apperley J et al. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma - a retrospective case-matched study from the European Group for Blood and Marrow Transplantation. Blood 1996; 88: 4711-4718.
45. Storb R, Yu C, Sandmaier B, McSweeney P, Georges G, Nash R et al. Mixed hematopoietic chimerism after hematopoietic stem cell allografts. Transplant Proc 1999; 31: 677-678.
46. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390-3400.
47. Hoepfner S, Probst SM, Breitkreutz I, Moehler T, Benner A, Goldschmidt H et al. Non-myeloablative allogeneic transplantation as part of salvage therapy for relapse of multiple myeloma after autologous transplantation. Blood 2002; 100 (Part 1): 859a, no. 3387-.
48. Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P et al. Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma. Bone Marrow Transplant 2002; 30: 367-373.
49. Einsele H, Schafer HJ, Hebart H, Bader P, Meisner C, Plasswilm L et al. Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning. Br J Haematol 2003; 121: 411-418.
50. Kröger N, Perez-Simon JA, Myint H, Klingemann H, Shimoni A, Nagler A et al. Relapse to prior autograft and chronic graft-versus-host disease are the strongest prognostic factors for outcome of melphalan/ fludarabine-based dose-reduced allogeneic stem cell transplantation in patients with multiple myeloma. Biol Blood Marrow Transplant 2004; 10: 698-708.
51. Crawley C, Iacobelli S, Björkstrand B, Apperley JF, Niederwieser D, Gahrton G. Reduced-intensity conditioning for myeloma: Lower nonrelapse mortality but higher relapse rates compared with myeloablative conditioning. Blood 2007; 109: 3588-3594.
52. Qazilbash MH, Saliba R, de Lima M, Hosing C, Couriel D, Aleman A et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 2006; 106: 1084-1089.
53. Elice F, Raimondi R, Tosetto A, D'Emilio A, Di Bona E, Piccin A et al Prolonged overall survival with second on-demand autologous transplant in multiple myeloma. Am J Hematol 2006; 81: 426-431.
54. Maloney DG, Molina AJ, Sahebi F, Stockerl-Goldstein KE, Sandmaier BM, Bensinger W et al. Allografting with nonmyelo-ablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma. Blood 2003; 102: 3447-3454.
55. Rotta M, Storer B, Sahebi F, Shizuru JA, Benedetto B, Lange T et al Long-term outcome of autologous followed by nonmyeloablative allografting from HLA-identical sibling for multiple myeloma (MM). Blood 2007; 110 (Part 1): 889a, no. 3029 (abstract).
56. Lee C-K, Badros A, Barlogie B, Morris C, Zangari M, Fassas A et al Prognostic factors in allogeneic transplantation for patients with high-risk multiple myeloma after reduced intensity conditioning. Exp Hematol 2003; 31: 73-80.
57. Kroger N, Schwerdtfeger R, Kiehl M, Sayer HG, Renges H, Zabelina T et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood 2002; 100: 755-760.
58. Kroger N, Sayer HG, Schwerdtfeger R, Kiehl M, Nagler A, Renges H et al. Unrelated stem cell transplantation in multiple myeloma after a reduced-intensity conditioning with pretransplantation antithymocyte globulin is highly effective with low transplantation-related mortality. Blood 2002; 100: 3919-3924.
59. Galimberti S, Benedetti E, Morabito F, Papineschi F, Callea V, Fazzi R et al. Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation. Leuk Res 2005; 29: 961-966.
60. Pérez-Simón JA, Martino R, Alegre A, Tomás JF, De Leon A, Caballero D et al. Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. Br J Haematol 2003; 121: 104-108.
61. Vesole DH, Zhang L, Flomenberg N, Greipp PR, Lazarus HM. A phase II trial of autologous stem cell transplant (AHSCT) followed by mini-allogeneic stem cell transplant (AlloTx) for the treatment of multiple myeloma: Analysis of ECOG E4A98. Blood 2007; 110 (Part 1): 889A, no. 3027 (abstract).
62. Rosiñol L, Pérez-Simón JA, Sureda A, de la Rubia J, de Arriba F, Lahuerta JJ et al. A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma. Blood 2008; 112: 3591-3593.
63. Garban F, Attal M, Michallet M, Hulin C, Bourhis JH, Yakoub-Agha I et al. Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma. Blood 2006; 107: 3474-3480.
64. Bruno B, Rotta M, Patriarca F, Mordini N, Allione B, Camevale-Schianca F et al. A comparison of allografting with autografting for newly diagnosed myeloma. N Engl J Med 2007; 356: 1110-1120.
65. Kroger N, Schilling G, Einsele H, Liebisch P, Shimoni A, Nagler A et al. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood 2004; 103: 4056-4061.
66. Schilling G, Hansen T, Shimoni A, Zabelina T, Simon-Perez JA, Gutierrez NC et al. Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma. Leukemia 2008; 22: 1250-1255.